CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Olopatadine 0.1% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00818805
NCT00818805Phase 4Completed
CompareCT.gov

Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

Alcon Research·interventional·Posted Jan 8, 2009·Updated Jun 4, 2012

In Brief

A Phase 4 clinical trial evaluating Olopatadine 0.1%, Tranilast 0.5%, and 2 other interventions for Allergic Conjunctivitis. Completed, enrolled 50 participants.

Detailed Summary

To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 8, 2009
Enrollment StartJul 1, 2008
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.5 years ago

Interventions

Olopatadine 0.1%drug

one drop in one eye

Tranilast 0.5%drug

one drop in one eye

Placebo (Olopatadine)drug

one drop in contralateral eye

Placebo (Tranilast)drug

one drop in contralateral eye